FDA Announces 2024 NYTS Data and PATH Webinar

Regulations by 2FIRSTS.ai
Dec.19.2024
FDA Announces 2024 NYTS Data and PATH Webinar
FDA releases 2024 NYTS data showing record low youth tobacco use, PATH webinar announcement. Join now for important findings.

On December 18th, the Food and Drug Administration (FDA) released the 2024 NYTS data research results and announced an upcoming webinar for the PATH (Population Assessment of Tobacco and Health) network.

 

Teen Tobacco Product Usage Rates are at Their Lowest Level in 25 Years, but Disparities still Exist

 

The use of tobacco products among middle and high school students in the United States has dropped to its lowest level in 25 years, according to data released by the 2024 National Youth Tobacco Survey (NYTS). In the past year alone, at least 500,000 fewer students are using tobacco products.

 

In 2024, approximately 2.25 million middle and high school students reported using at least one tobacco product in the past 30 days, compared to 2.8 million in 2023. A significant decrease in e-cigarette use is the main factor for this decline, with 2.13 million adolescents using e-cigarettes in 2023 compared to 1.63 million in 2024. Cigarette use also reached its lowest level in survey history, with only 1.4% of students reporting current use in 2024.

 

Progress varies among different groups. Between 2023 and 2024, there was a significant decrease in the use of tobacco products, e-cigarettes, and various tobacco products among female students. Hispanic students also showed a downward trend during the same period. However, among non-Hispanic American Indian or Alaska Native students, the use of various tobacco products has increased, and non-Hispanic white students have also seen an increase in the use of nicotine pouches.

 

PATH Study: Release of the 7th Wave of PATH Study Biomarker Data File

 

The Food and Drug Administration's Center for Tobacco Products and the National Institute on Drug Abuse, a subsidiary of the National Institutes of Health, have released the seventh wave of the Biomarker Restricted Use Files (BRUF) collected between January 2022 and April 2023. Researchers can apply to access this data. This is the first time the seventh wave of biomarker data files has been included.

 

The first wave of sample data was also expanded to include adults who had previously experimented with or used tobacco products long-term.

 

FDA is Set to Hold a Large-scale Online Seminar on PATH Study

 

On January 9, 2025, the FDA will discuss key findings from the Population Assessment of Tobacco and Health (PATH) study in a web seminar. Over the past decade, this longitudinal study has tracked significant changes in tobacco product use, including the sharp increase and decrease in e-cigarette use, the emergence of new products such as nicotine pouches, and the growing concern about the concurrent use of multiple tobacco products. The seminar will provide an overview of the PATH study, highlighting how the scientific evidence it has generated guides FDA regulatory activities and public health efforts.

 

In recent comments and public meetings, leaders of the NIH and FDA have called for innovative smoking cessation treatments.

 

Leaders from the FDA and NIH have published a new commentary in the Annals of Internal Medicine, calling for innovative approaches in the development of smoking cessation treatments. The article emphasizes the need for active participation in smoking cessation research from stakeholders including clinicians, academia, industry, public health, and patient advocacy groups. Discussions and recommendations are made to promote research and development of smoking cessation therapies, with a focus on studying the long-term health effects of e-cigarettes and their toxicology. Furthermore, the FDA and NIH held a public meeting in October titled "Advancing Tobacco Cessation: Priorities for FDA and NIH," which focused on the development of innovative smoking cessation products to assist both adults and youth. The public comment period has been extended until December 20, 2024, allowing the public to share insights, data, and recommendations on advancing innovative smoking cessation products and therapies to help youth and adults.

 

FDA Issues Regulatory Science Policy Memorandum Related to Pre-market Application Review

 

In November of this year, the FDA released additional regulatory science policy memoranda related to premarket application reviews by the agency. This release included 13 memoranda from 2020 to 2023, outlining processes and prioritization methods for filing and reviewing premarket tobacco product applications (PMTAs) for flavored e-cigarettes and other products, as well as the basis for specific actions supporting environmental assessments. These scientific policy memoranda provide the FDA's views on specific topics at particular points in time, which may be updated due to policy changes.

 

In April, the FDA resumed the release of regulatory science policy memoranda. This is the fourth batch of memoranda released in 2024, including the one released today, bringing the total number of memoranda released by the FDA to 26.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Japanese Addiction Psychiatrist Says Complete Abstinence Is Not Always the Goal of Harm Reduction | 2Firsts Interview
Complete abstinence is not always the goal of addiction treatment under a harm-reduction approach, Japanese psychiatrist Tomohiro Shirasaka told 2Firsts in Manila. In the interview, he discussed patients' quality of life, Japan's shift towards heated tobacco products, and the challenges of quitting smoking for people with mental illness. Drawing on addiction treatment work in the Philippines, he advocated support rather than punishment and questioned whether fear-based health warnings effectively address the reasons people continue smoking.
Nov.10
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Special Report | How Capital Is Reassessing the Global Tobacco and Modern Nicotine Industry: Lessons from a New York Forum
Capital is reassessing the global tobacco and modern nicotine industry as heated tobacco, vaping and nicotine pouches reshape demand, profitability and regulation. At the 2026 New Approaches Summit in New York, investors and analysts examined whether smoke-free growth can sustain earnings, how regulation shapes startup value, and whether shareholder engagement can be more effective than divestment. The debate points to a broader shift: tobacco transition is increasingly becoming a capital-allocation, governance and valuation question.
Capital Markets
Oct.05
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Product | Philip Morris Korea Launches Two TEREA ONYX Capsule Tobacco Sticks, Expanding Portfolio to Five Lines
Philip Morris Korea launched TEREA ONYX, a new tobacco stick line for IQOS ILUMA devices, on October 15, 2026. The initial products, AMANG PEARL and CALI PEARL, feature tropical-inspired flavors, Fresh Filters and capsules designed to deliver different flavor experiences before and after activation. Both are priced at KRW 4,800 per pack and are available at convenience stores nationwide and IQOS-operated stores in South Korea. The launch expands the Korean TEREA portfolio from four product lines to five, following earlier capsule tobacco stick additions in 2026.
product
Oct.23
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Product | Japan Tobacco Expands Nordic Spirit Nicotine Pouch Range to Eight SKUs in Japan, Launches Melon Variant and Broadens Mint Retail Distribution
Japan Tobacco Inc. (JT) launched Nordic Spirit Rich Melon Medium through selected tobacco retailers in Japan on November 2, 2026, while expanding physical retail distribution for three existing mint products previously sold through the CLUB JT online store. The melon launch brings Nordic Spirit's Japanese portfolio to eight SKUs. All four products are manufactured in Sweden, contain a standard 14 pouches per can and retail for ¥500 including tax. Since introducing Nordic Spirit in Japan in March, JT has expanded the brand's product lineup and distribution through its online store, convenience stores and selected tobacco retailers.
product
Nov.04
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia Reviews Possible Refund of $92 Million in Vape Taxes After Court Rules 2023 Nicotine Exemption Unlawful
Malaysia's Ministry of Finance said in a written parliamentary reply on November 17, 2026, that it was examining whether a court ruling concerning the country's 2023 liquid-nicotine exemption affected the legal basis for vape excise duties already collected. Royal Malaysian Customs Department records show that the government has collected RM377.08 million (approximately $92 million) in vape-related excise duties since May 2023, with the proceeds transferred to the federal Consolidated Fund. In May, the Kuala Lumpur High Court ruled that the 2023 decision to exempt liquid and gel nicotine used in vaping products from the Poisons List was unlawful. The government withdrew its appeal in August but has not decided whether the taxes should be refunded. The Finance Ministry is also seeking the Health Ministry's position on future vaping regulation.
Regulations
Nov.19
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Special Report|CrossBar's High-Puff Vapes Draw Attention on Pennsylvania's 163-Product Directory as Link Between Earlier 1.3mL PMTA Filings and New 13mL Products Remains Unclear
Pennsylvania began enforcing its electronic nicotine delivery system directory restrictions on October 19, 2026. Among 163 product listings recorded before enforcement, four CrossBar 20K disposables stood out with 13mL capacity, advertised puff counts of up to 20,000 and a flattened design distinct from conventional pod systems and compact disposables. Historical records identify earlier 1.3mL CrossBar products associated with Romo LLC, while newer 13mL products appeared in several state directories beginning in 2025 under entities including Blue Nine LLC. PMTA compliance expert Mr. K identified amendments and application ownership transfers as possible regulatory mechanisms, although neither has been confirmed in this case. Separately, Reynolds' $7.5 million acquisition of 16 PACHA products and related assets illustrates the commercial value of products linked to historic PMTA submissions.
Special Report
Oct.22